Solid state forms of alrizomadlin and process for preparation thereof
The development of crystalline polymorphs of Alrizomadlin addresses the need for improved solid-state forms by enhancing stability and solubility, enabling effective pharmaceutical compositions for cancer treatment.
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- ASSIA CHEM IND
- Filing Date
- 2025-11-28
- Publication Date
- 2026-06-04
AI Technical Summary
There is a need for additional solid-state forms of Alrizomadlin, including crystalline polymorphs, to improve processing properties, stability, and bioavailability for the treatment of various types of cancers.
The development of crystalline polymorphs of Alrizomadlin, such as Forms AZ1 to AZ6, and their solvates, which are characterized by specific X-ray powder diffraction patterns and solid state13C NMR spectra, offering improved chemical stability, solubility, and handling characteristics.
The crystalline polymorphs provide enhanced stability, solubility, and processing properties, facilitating the development of pharmaceutical compositions for treating cancers like salivary gland cancer, acute myeloid leukemia, chronic myelomonocytic leukemia, solid tumors, melanoma, lung cancer, neuroblastoma, and mesothelioma.
Smart Images
Figure IB2025062208_04062026_PF_FP_ABST